Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Emil Holding II is a Luxembourg-based holding company that serves as the parent entity for the Schülke & Mayr Group (schülke). The company specializes in infection prevention and hygiene solutions, providing a wide range of disinfectants, antiseptics, and skin care products for healthcare, industrial, and consumer markets. Following its acquisition by the investment firm ATHOS (the Strüngmann family office) from EQT in 2023, Emil Holding II oversees the strategic operations and global distribution of schülke's hygiene portfolio. The group is a market leader in the DACH region and maintains a significant international presence in the hygiene and infection control sector.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Emil Holding II.